Summary of Investments Made

$91.8M
Total to date

By Funding Area – In $Millions

$21.8
Discovery
$50.4
Clinical
$1.1
Manufacturing
$0
Introduction and Delivery
$9.5
Real World Evidence and Data Platforms
$9
Diagnostics

Clinical Investments

Filter Investments:
Sort by:
Use Case
Title
Description

Use Case: Pre-exposure Prophylaxis

Title: Henry Ford Health System WHIP Trial

Description:

Started early April in Michigan and Ohio and will target 3,000 health workers and first responders using hydroxychloroquine as pre-exposure prophylaxis. Currently at ~20% enrollment. This trial is expanding nationally to Texas, Arizona, and Florida and internationally to Brazil, Peru, Ecuador and Mexico. 

Use Case: Pre-exposure Prophylaxis

Title: University of Oxford / Mahidol Oxford Tropical Medicine Research Unit (MORU) COPCOV Trial

Description:

Began at the end of March and uses hydroxychloroquine and chloroquine as pre-exposure prophylaxis. This will target 40,000 health workers, hospital inpatients and inpatient relatives who may become exposed to COVID-19. It is currently enrolling in Thailand, UK, South America, and Indonesia.

Use Case: Pre-exposure Prophylaxis

Title: Washington University of St. Louis CROWN CORONATION Trial

Description:

The study began in September 2020 and seeks to include up to 30,000 health workers globally to determine the efficacy of the MR/MMR vaccine as pre-exposure prophylaxis. Sites in the US and South Africa have begun recruiting. Ghana is likely to host the next site followed by Zambia, Zimbabwe and Uganda.

Use Case: Post-exposure Prophylaxis

Title: University of Washington: Post-exposure Prophylaxis Using Hydroxychloroquine

Description:

Aimed to test the efficacy of HCQ to prevent incidence of SARS-CoV-2 infection. The study has been completed.

Use Case: Prophylaxis

Title: Prophylaxis Registry Trial in Low and Middle-income Countries

Description:

Seeks to collect real-world evidence by capturing health workers’ self-initiated prophylaxis treatments and outcomes. The goal is to cover 10,000 health workers in six low- and middle-income country (LMIC) sites. Data collection started in early August, primarily in Pakistan. Study approval has been obtained for Nigeria, Uganda, Senegal, Zambia, and Kenya, where enrollment will begin shorty.

Use Case: Mild Disease Treatment

Title: AGILE – University of Liverpool

Description:

Phase I/II trial using the most modern and innovative statistical methods allowing for multiple drugs to be tested in parallel, and to remove or add treatments faster than ever before, based on results of safety and efficacy.

Use Case: Mild Disease Treatment

Title: AVID-CC trial, University of Oxford

Description:

Phase II trial aiming to establish whether treatment with adalimumab is associated with a lower rate of progression to severe COVID-19 disease in community care settings, primarily in care homes. Enrollment is set to begin in Q4 2020.  

Use Case: Mild Disease Treatment

Title: Medicines for Malaria Ventures ReACT trial

Description:

Exploratory study being conducted in South Africa using five different experimental treatment arms versus standard of care for the treatment of COVID-19 infection in symptomatic outpatients with mild disease at the time of enrollment.

Use Case: Mild Disease Treatment

Title: Montreal Heart Institute COLCORONA Trial: Mild Disease Treatment Using Colchicine

Description:

Started in March in Quebec and has since expanded to Spain, New York and California. This trial is targeting 6,000 outpatients using Colchicine to treat mild COVID-19. Given positive interim read-outs in June, this trial is expending to Brazil, Argentina and South Africa. ~37% enrollment completed. 

Use Case: Mild Disease Treatment

Title: University of Washington high risk outpatient trial

Description:

Targets high-risk patients in the outpatient setting initially using hydroxychloroquine (HCQ), HCQ + azithromycin (AZ), and Kaletra to treat mild COVID-19. HCQ and HCQ+AZ arms were discontinued in late July and the study is moving forward with Kaletra.